<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">09070</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2023.09070</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Allergologie / Immunologie</subject>
          <subject>Angiologie</subject>
          <subject>Dermatologie und Venerologie</subject>
          <subject>Hämatologie</subject>
          <subject>Pathologie / Histologie</subject>
          <subject>Syndrome</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Livedo racemosa als Manifestation eines Antiphospholipid-Syndroms</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Röthlin</surname>
            <given-names>Andrea</given-names>
          </name>
          <email>allegra.r@icloud.com</email>
          <aff>Assistenzärztin | Innere Medizin | Spitalstrasse | Luzern | 6004 | SWITZERLAND | 076 395 33 18</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Buser</surname>
            <given-names>Claudia</given-names>
          </name>
          <email>claudia.buser@luks.ch</email>
          <aff>Innere Medizin</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2023.03.08">
        <day>08</day>
        <month>03</month>
        <year>2023</year>
      </pub-date>
      <volume>23</volume>
      <issue>10</issue>
      <fpage>950</fpage>
      <lpage>953</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Wir berichten über eine 57-jährige Patientin mit ausgedehnter Livedo racemosa an den unteren Extremitäten und im Wangenbereich. Die Laboruntersuchungen ergaben positive Antiphospholipid-Antikörper vom Typ Anti-Kardiolipin-Antikörper IgM und Anti-β-2-Glykoprotein I-Antikörper IgM. Bei klinisch erfüllten Kriterien bestand der Verdacht auf ein Antiphospholipid-Syndrom. Es wurde eine Kompressionstherapie und therapeutische Antikoagulation mit Fragmin® s.c. eingeleitet, welche man nach 3 Wochen überlappend auf Aspirin Cardio® 100 mg/d p.o. umstellte. Zudem erfolgte bei Nekrosegefahr, im Bereich einzelner Racemosaläsionen, eine kurzzeitige Verabreichung von Prednisolon 40mg/d p.o. In der Verlaufskontrolle nach drei Monaten waren die Läsionen vollständig abgeheilt und die Laborfolgebestimmungen zeigten ein moderates Antikörper-Risikoprofil. Mit diesem Befund war auch das Labor-Kriterium erfüllt und damit die Diagnose eines Antiphospholipid-Syndroms gestellt.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
